<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392415</url>
  </required_header>
  <id_info>
    <org_study_id>N-20170063</org_study_id>
    <nct_id>NCT03392415</nct_id>
  </id_info>
  <brief_title>The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion</brief_title>
  <acronym>NOBLE-CTO</acronym>
  <official_title>The NOrdic-Baltic Randomized Registry Study for Long-term Clinical Evaluation of Adjunction of PCI to Optimal Medical Therapy in Chronic Total Coronary Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leif Thuesen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized registry for the study of CTO PCI as adjunction to optimal medical therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized registry with option of crossover after 6months</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>a minimal follow-up of 6 months</time_frame>
    <description>All-cause mortality after inclusion of 2000 patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>6 months.</time_frame>
    <description>Quality of life assessment by 12-Item Short Form Survey Instrument (SF-12v2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MR perfusion</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of inducible myocardial perfusion defect evaluated, improvement of left ventricular function and correlation of angina and perfusion defect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>evaluation of systolic and diastolic left ventricular function compared to index echocardiography before CTO PCI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Socio-economic</measure>
    <time_frame>1 year</time_frame>
    <description>Socio-economic consequenses of CTO PCI. Treatment cost compared to coronary bypass surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <condition>Heart Failure</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Initial conservative treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>initial interventional treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTO PCI attempt as initial strategy with medical optimization simultaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CTO PCI</intervention_name>
    <description>attempted percutaneous coronary intervention of the chronic total coronary occlusion</description>
    <arm_group_label>Initial conservative treatment</arm_group_label>
    <arm_group_label>initial interventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥1 CTO lesion amenable to PCI.

          -  Stable and stabilized coronary artery disease

          -  Symptoms (angina pectoris or shortness of breath) and/or signs of reversible perfusion
             defect by SPECT, PET or MR and/or angiographic/echocardiographic indication of
             reversible ischemia.

          -  CTO lesion in a major coronary vessel supplying a significant myocardial territory
             (vessel diameter usually ≥3mm).

        Exclusion Criteria:

          -  Expected survival &lt;1 year.

          -  Renal failure on dialysis.

          -  Stable non-CTO lesions treated within one month.

          -  Declined informed consent.

          -  Regarding CMR: allergy to contrast medium, severe obesity, claustrophobia and certain
             metallic implants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren Pihlkjær Hjortshøj, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin K Christensen, MD</last_name>
    <phone>+45 9766 4454</phone>
    <email>m.kirk@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leif Thuesen, MD</last_name>
    <phone>+45 9766 4465</phone>
    <email>leif.thuesen@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leif Thuesen, MD</last_name>
      <phone>+4522328264</phone>
      <email>leif.thuesen@rn.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>October 13, 2019</last_update_submitted>
  <last_update_submitted_qc>October 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Leif Thuesen</investigator_full_name>
    <investigator_title>Senior consultant</investigator_title>
  </responsible_party>
  <keyword>chronic total occlusion</keyword>
  <keyword>CTO</keyword>
  <keyword>PCI</keyword>
  <keyword>percutaneus coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03392415/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

